DaVita SG&A Expenses 2010-2024 | DVA

DaVita sg&a expenses for the twelve months ending December 31, 2024 were $1.538B, a 4.37% increase year-over-year.

  • DaVita annual sg&a expenses for 2024 were $1.538B, a 4.37% increase from 2023.
  • DaVita annual sg&a expenses for 2023 were $1.474B, a 8.77% increase from 2022.
  • DaVita annual sg&a expenses for 2022 were $1.355B, a 13.37% increase from 2021.

DaVita SG&A Expenses 2010-2024 | DVA

  • DaVita annual sg&a expenses for 2024 were $1.538B, a 4.37% increase from 2023.
  • DaVita annual sg&a expenses for 2023 were $1.474B, a 8.77% increase from 2022.
  • DaVita annual sg&a expenses for 2022 were $1.355B, a 13.37% increase from 2021.
Related Stocks
Company NameMarket
Cap
Fresenius SE (FSNUY)$21.5B
Quest Diagnostics (DGX)$19.2B
Encompass Health (EHC)$10.2B
Chemed (CHE)$8.4B
Elanco Animal Health (ELAN)$5.6B
Option Care Health (OPCH)$5.5B
RadNet (RDNT)$4.8B
LifeStance Health (LFST)$3.1B
Amedisys (AMED)$3B
Astrana Health (ASTH)$2.2B
Addus HomeCare (ADUS)$2.1B
U.S Physical Therapy (USPH)$1.3B
Aveanna Healthcare Holdings (AVAH)$968M
Pennant (PNTG)$927M
Atai Life Sciences (ATAI)$351M
Bioqual (BIOQ)$54M
Daxor (DXR)$35M
Ontrak (OTRK)$7M
MEDIROM Healthcare Technologies (MRM)$4M
IMAC Holdings (BACK)$1M
Psychemedics (PMD)$0M